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Abstract 1 
Background.  While  β -blockers  can be effective in controll ing 2 
tachyarrhythmias  after  pediatr ic  cardiac surgery,  a  negat ive inotropic  3 
inf luence somet imes complicates their  use. Landiolol  hydrochlor ide is a  novel ,  4 
ul t ra-shor t -act ing β -blocker  recent ly developed in Japan.  The drug has  higher  5 
β1/β2 selectivi ty rat io and a  less  negative inotropic  effect .  This  s tudy 6 
retrospectively evaluates  the eff icacy and safety of  landiolol  in  the 7 
management  of  tachyarrhythmias  af ter  pediat r ic  cardiac surgery.  8 
Methods.  A retrospective analysis  was performed on 312 consecut ive 9 
pat ients  undergoing surgery for  congeni tal  hear t  disease.  Twelve pat ients  were 10 
t reated with landiolol  for  cr i t ical  tachyarrhythmia.  The mean age of  patients  11 
was 28.7 ± 10.6 months.  Five junct ional  ectopic  tachycardia ,  2  at ria l  f lut ters ,  12 
1 paroxysmal  supraventr icular  tachycardia ,  1  at ria l  f ibr i l la t ion,  1  13 
at rioventricular  reciprocating tachycardia  wi th Wolff  - Parkinson White  14 
Syndrome and 2 excessive s inus tachycardia were treated. 15 
Results .  The mean loading and maintenance doses  were 11.3 ± 4.0 and 6.8 ± 16 
0.9 μg  /  kg /  min,  respect ively.  Rate  control  was achieved in all  pat ients .  17 
Landiolol  reduced the heart  rate  from 169.7 ± 11.4 to 127.7 ± 7.5 bpm 18 
(p<0.05)  whi le  blood pressure did not  s ignif icant ly change.  Tachyarrhythmias  19 
were conver ted to s inus rhythm in 70.0% of the cases  and the average t ime 20 
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needed to achieve hear t  ra te  reduct ion was 2.3 ± 0.5 hours .   1 
Conclusions.  Landiolol  was eff icacious in treating tachyarrhythmia in 2 
pediat ric  cardiac surgery.  The desi red negative chronotropic  effect  was 3 
achieved without  s ignif icant  hemodynamic compromise.  The ul tra-shor t  4 
half -l i fe  of  landiolol  provided rapid dose manipulation.  This s tudy suggests  5 
that  landiolol  is  a  promising opt ion for  the management  of  postoperative 6 
tachyarrhythmias  in  pediat r ic  pat ients .   7 
(255words) 8 
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Intractable  tachyarrhythmia af ter  pediat r ic  cardiac surgery can quickly 1 
lead to hemodynamic instabil i ty and requires  prompt  management  1  2  3 .  While  2 
β -blockers  can be effect ive in controll ing these tachyarrhythmias ,  a  negat ive 3 
inotropic  inf luence somet imes complicates  their  use  4 .   4 
Landiolol  hydrochlor ide (Ono Pharmaceutical  Co,  Ltd,  Osaka,  Japan)  is  a 5 
novel  ul tra-shor t -act ing β -blocker  developed in Japan.  Plasma half -l i fe  of  the 6 
drug is  4  minutes .  It  has  a  higher  β1/β2 select ivi ty rat io  and as  a result  a  less  7 
pronounced negat ive inotropic  effect  compared with other  intravenous 8 
β -blockers  5 .  Landiolol  has  become a common therapeut ic  option for  the 9 
management  of  postoperative tachyarrhythmia in  adult  pat ients  in  Japan 6  7 .  10 
However,  l i t t le  has  been reported regarding i ts  use  in pediatr ic  patients .   11 
We report  our exper ience with landiolol  in  postoperat ive pediatr ic  12 
cardiac surgical  pat ients  suffering f rom intractable  tachyarrhythmia.   13 
 14 
Patients  and Methods 15 
Between 2006 and 2012,  312 patients  underwent  open heart  surgery for  16 
congeni tal  hear t  disease at  the Tsukuba Universi ty hospital .  Twelve of  these 17 
pat ients  developed intractable  tachyarrhythmia af ter  surgery and were treated 18 
with landiolol .  The study was approved by the Universi ty of  Tsukuba 19 
Inst i tut ional  Review Board and patient  records were analyzed ret rospectively.   20 
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In al l  pat ients  tachyarrhythmia resulted in hemodynamic instabil i ty,  and 1 
was t reated with a  s tandard protocol  which included cooling for  hyper thermia,  2 
sedation,  elect rolyte  imbalance management  and minimizat ion of  int ravenous 3 
catecholamine infusion i f  possible .   4 
In  the ear l ier  cases ,  the adminis t rat ion of  landiolol  was ini t ia ted at  40 μg  5 
/  kg /  min for  loading and gradually decreased into the recommended 6 
maintenance dose of  10 to 40μg  /  kg /  min according to the pharmaceutical  7 
reference.  In la ter  cases ,  the  adminis tration of  landiolol  was s tar ted with a  8 
relat ively low dose at  3-5 μg  /  kg /  min with special  concern for  excessive 9 
negat ive chronotropic effect  wi th a  loading of  40 μg  /  kg /  min s ince we 10 
experienced one case that  developed excessive bradycardia  wi th the init ia l  11 
protocol .  The maintenance dose of  landiolol  was set t led at  the lowest  effect ive 12 
dose needed to sustain s inus rhythm or  adequate  heart  rate  with stabi l ized 13 
hemodynamics.   14 
 15 
Statist ical  analysis  16 
All  values  are  expressed as  the mean ± standard error  of  the mean.  17 
Stat is t ical  analysis  was performed using the Wilcoxon signed-rank test  to  18 
compare pre- and post-adminis t rat ion heart  ra te  and systol ic  blood pressure .  19 
SPSS 19.0 for  windows (SPSS Inc,  Chicago,  IL)  was used for  analyses .   20 
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 1 
Results 2 
The characteris t ics  of  the 12 pat ients  t reated with landiolol  are  l is ted in 3 
Table 1.  The mean age of  pat ients  was 28 ± 10 months ( range,  10 days to 108 4 
months) .  There were 5 junctional  ectopic  tachycardia  (JET),  2  at ria l  f lutter,  1  5 
paroxysmal  supraventr icular  tachycardia  (PSVT),  1  at rial  f ibri l la t ion,  1  6 
at rioventricular  reciprocating tachycardia  (AVRT) by Wolff-Parkinson-White  7 
(WPW) syndrome and 2 excessive s inus tachycardia .  Digoxin and l idocaine 8 
were used in 2 cases  before the adminis tra t ion of  landiolol .   9 
 The mean loading dose was 11.3 ± 4.0 μg  /  kg /  min and the maintenance 10 
dose was 6.8 ± 0.9 μg  /  kg /  min.  Landiolol  reduced the heart  rate  signif icantly 11 
from 169.7 ± 11.4 to 127.7 ± 7.5 beats  /  minute  (Figure 1) ,  whi le  pre- and 12 
post-adminis trat ion systolic  blood pressure did not  s ignificant ly change.  The 13 
average t ime needed to achieve a 20% hear t  ra te reduct ion was 2.3 ± 0.4 hours 14 
(Table 2) .  15 
 Tachyarrhythmias  16 
were conver ted to regular  sinus rhythms in 70 % of  cases  and the f inal  average 17 
percent  reduct ion in hear t  rate  was 23.7 ± 4.2 %. One neonate among the 18 
ear l ier  cases rapidly developed an excessive bradycardia wi th heart  ra te below 19 
100 beats /  min at  48 hours  after the onset  of  landiolol  infusion with 10.0 μg  /  20 
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kg /  min.  Hemodynamic stabil i ty was reestabl ished by immediate  cessat ion of  1 
landiolol  and introduct ion of  a tr ia l  pacing.  Hear t  ra te  was maintained under  2 
at ria l  pacing without  res tar t  of  landiolol .  3 
Comment 4 
 The efficacy of  β -blockade in t reating tachyarrhythmia af ter  cardiac 5 
surgery is  widely recognized.  Despi te  this  the myocardial  depressant  effects  6 
of  these drugs complicates  their  use.   7 
 Landiolol  i s  a  novel  ul t ra-shor t -act ing β -blockade which has  a  plasma 8 
half -l i fe  of  4 minutes  5 .  Landiolol  was developed in Japan and released in 9 
2002.  In a  recent  randomized control  s tudy,  Sezai  e t  a l .  reported that  landiolol  10 
adminis t rat ion s ignif icantly reduced the occurrence of  a tr ial  f ibri l la t ion and 11 
heart  rate  in  patients  af ter  adul t  cardiac surgery without  s ignificant  change in 12 
blood pressure 7 .  Another  prospect ive mult icenter  randomized s tudy in adul t  13 
pat ients  (JL-KNIGHT) was also recent ly under taken in Japan.  In this study, 14 
landiolol  was effective for  the conversion of  a t rial  f ibri l la t ion to s inus rhythm 15 
af ter  open heart  surgery with a  lower incidence of hypotension 8 .  The drug has 16 
been widely used in Japan and recognized as  one of  the useful  options for  the 17 
management  of  postoperative tachyarrhythmias  in  adul t  pat ients .  However,  18 
unt i l  now the efficacy of  landiolol  in  pediat ric  cardiac surgery patients has not 19 
been publ ished.  The present  study reports  our  earl ies t  exper ience.  20 
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β -adrenergic  receptors are  subdivided into two basic  types .  β1-receptors  1 
exist  in  the myocardium and their  st imulation has  both inotropic  and 2 
chronotropic  effects .   β2-receptors  exis t  in smooth muscle  cel ls  and their  3 
s t imulation results  in  bronchodi lat ion and vasodilation.  β -blockades are 4 
character ized by the select ivi ty for  β1  and β2 s t imulation.  There are  3 5 
β -blockades avai lable  for  int ravenous inject ion at  present .  One is  propranolol  6 
which has  a low β1  /  β2 selectivi ty rat io  of  0.6 and a long plasma half -l i fe  of  7 
120 min.  Because of  i t s  st rong negat ive inotropic  effect  and long half-l i fe ,  8 
propranolol  is  not  the drug of  choice for  cri t ical  care  after  pediatr ic  cardiac  9 
surgery.  Esmolol  hydrochloride is  another  β-blockade which has a higher  β1  /  10 
β2 selectivi ty rat io  of  20 and a plasma half -l i fe  of  9 minutes  9 .  Esmolol  has  11 
been also commercial ly avai lable  in  Japan s ince 2002.  Compared with these 12 
int ravenous β -blockades,  landiolol  has  the shor test  plasma half -l i fe  of  4 13 
minutes  and the highest  β1 /  β2 selectivi ty rat io  of  277.   14 
 Ikeshi ta  e t  a l .  reported that  landiolol  and esmolol  had equipotent 15 
negat ive chronotropic effects .  However ,  landiolol  showed less  of  a  negat ive 16 
inotropic  effect  including the maximal  rate  of  lef t  ventr icular  force 17 
development  (LVdP /  dtmax )  while  esmolol  demonstrated a  st rong inhibi tory 18 
effect  1 0 ,  1 1 .   19 
In our  cases ,  more than 20 % heart  rate  reduct ion was achieved in al l  20 
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pat ients  wi thout  decrease in blood pressure  by landiolol .  Also rhythm 1 
conversion was obtained in 70 % of  patients.  These results  are  consis tent  with 2 
previous studies  which demonstrate  the s trong negat ive chronotropic  effect  3 
without negat ive inotropic  effect  of  landiolol  in  adult  patients  af ter  cardiac 4 
surgery 7  8 .  Addi t ionally,  Shibata et  al .  reported that  landiolol  had no 5 
apparent  effects  on the action potent ial  or  ionic  currents  of  ventricular  6 
myocytes ,  whi le  esmolol  shor tened action potential  durat ion and demonstrated 7 
a  negat ive inotropic  effect  in  a  dose related fashion.  1 2 .  This  could explain 8 
why landiolol  has  less negat ive inotropic  effect .  However,  the detai led 9 
mechanism is  s t i l l  unknown and fur ther  invest igation is  needed.   10 
 The efficacy of  other  ant iarrhythmic drugs is  widely recognized,  though 11 
there are possible  adverse side effects  such as  bradycardia ,  hypotension or  12 
proarrythmia 1  4  1 3  1 4 .  Amiodarone is  recognized as  one of  the most  potent  13 
drugs for  the management  of  arrhythmias  and i ts  efficacy in the management  14 
of  cri t ical  tachyarrhythmia in pediat ric  pat ients  has  been reported 1 5  1 6 .  15 
However,  in  Japan,  intravenous administ rat ion of amiodarone was approved in 16 
2007,  and landiolol  was released a  l i t t le  earl ier  than amiodarone.  We started 17 
using landiolol  as  a  f irs t  l ine drug for  tachyarrhythmia to preserve 18 
hemodynamics before the commercial  release of  amiodarone and we have seen 19 
the effectiveness  of  this  novel  drug.  Therefore we have no cl inical  exper ience 20 
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to contrast  landiolol  wi th amiodarone in pediatr ic  tachyarrhythmia.  1 
Amiodarone should be used with caut ion when t reating chi ldren because of  the 2 
adverse s ide effects  including a  36% rate  of  hypotension and a  20% rate  of  3 
bradycardia 1 3 .  Moreover  s ince the plasma half -l i fe of  amiodarone is  14 days, 4 
adverse s ide effects  could be prolonged when they appear  in  cr i t ical  si tuat ion. 5 
In contrast ,  the ult ra-shor t  half -l i fe  of  landiolol  provides  the advantage of  6 
rapid dose manipulation to maintain s table  hemodynamics  and this  may make 7 
landiolol  more sui table  for  emergency medical  care .  8 
 The recommended loading dose of  landiolol  based on the company’s  9 
instruct ion is  40 μg /  kg /  min and the maintenance dose is  10 μg /  kg /  min.  10 
However,  we exper ience one case of  bradycardia  which required atr ial  pacing.  11 
In addi t ion,  based on our  exper ience of  using landiolol  in  adult  pat ients  in  12 
JL-KNIGHT study 8 ,  we speculated that  the loading dose of  40 μg  /  kg /  min 13 
could be too much for pediat ric  pat ients .  Therefore,  we recommend a low 14 
start ing dose of  3 to  5 μg  /  kg /  min instead of  a  high loading dose,  and the 15 
dose should be increased gradually under  careful  hemodynamic observat ion 16 
with backup pacing.  17 
 18 
 19 
Limitations 20 
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 The numbers  of  cases  we have examined are relat ively smal l  to  have any 1 
s t rong conclusions.  Never theless  this  is  s t i l l  the country’s  largest  experience 2 
of  this  newly developed drug in pediatr ic  populat ion as  far  as  we know. Also 3 
our  s tudy did not  make comparisons of  landiolol  hydrochlor ide with other  4 
ant i -arrhythmia drugs including amiodarone. Fur ther  comparative studies  wi th 5 
other  anti -arrhythmia drugs and more informat ion in a  larger  ser ies  of  patients  6 
would be necessari ly to  assess  the effectiveness  of  landiolol  for  rate  and 7 
rhythm control  in  pediat ric  pat ients .   8 
 9 
Conclusion 10 
 Landiolol  was efficacious in t reat ing int ractable  tachyarrhythmia in 11 
pediat ric  pat ients after  cardiac surgery.  This s tudy suggests  that  landiolol  may 12 
be a  promising option for  the management  of  postoperative tachyarrhythmias  13 
in pediatr ic  patients .  14 
 15 
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Table 1.  Patient characteristic  
Case Diagnosis
Operative
procedure
Body
weight
(kg)
Sex Age
Bypass
time
(min)
Cross
clamp time
(min)
1 TGA ASO 3.3 M 10 days 269 106
2 IAA,VSD Ao repair + ICR 3.4 M 17 days 144 71
3 TOF ICR 8.4 M 1 year 151 91
4 Asplenia, SV Extra TCPC 13.7 M 5 years 157 69
5 DILV, CoA DKS+BDG 7.7 F 1 year 160 107
6 TAPVC TAPVCrepair 2.8 M 4 days 166 71
7 DORV DKS 7.0 M 1 year 257 68
8 Asplenia, PA BCPS 15.2 F 9 years 90 -
9 TGA Senning 5.2 M 30 days 179 107
10 HLHS NW 3.3 F 6 days 209 108
11 HOCM Myectomy 19.2 M 6 years 103 56
12 DILV, PS Extra TCPC 11.5 M 5 years 145 -
Mean 8.4 169.2 85.4
SE 1.6 15.5 6.5  
ASO: Aortic switch operation, BDG: Bidirectional Glenn, 
BCPS: Bidirectional cavopulmonary shunt, DILV: Double inlet left ventricle, 
DKS: Damus-Kaye-Stansel, DORV: Double outlet right ventricle, 
HLHS: Hypoplastic left heart syndrome, HOCM: Hypertrophic obstructive cardiomyopathy,  
IAA: Interrupted aortic arch, NW: Norwood operation, 
PA: Pulmonary atresia, PS: Pulmonary stenosis,  
SV: Single ventricle, TAPVC: Total anomalous pulmonary vein connection,  
TCPC: Total cavopulmonary connection, TOF: Tetralogy of Fallot,  
TGA: Transposition of great arteries, VSD: Ventricular septal defect, 
 
16 
TOKUNAGA ET AL 
LANDIOLOL FOR PEDIATRIC TACHYARRHYTHMIA 
Table 2.  Hemodynamic data of pre and post landiolol hydrochloride administration.  
Case
Type of
arrythmia
Sinus
conversion
Pre sBP
(mmHg)
Post sBP
(mmHg)
Pre HR
(bpm)
Post HR
(bpm)
Time to
20% HR
reduction(hr)
Time to SR
conversion
(hr)
Loadidng
dose of
landiolol
(μg/kg/min)
Maintenance
dose of
landiolol
(μg/kg/min)
 dosage of
dopamin
(γ）
 dosage of
PDEⅢ
inhibitor
(γ）
1 JET yes 48 56 195 163 6 10 40 10 7.5 0.25
2 JET no 75 72 219 175 1 - 3 8 3 0.5
3 JET yes 59 70 170 130 2 5 4 8 10 0.5
4 JET yes 73 72 130 100 1 5 5 10 5 0.5
5 JET yes 110 120 200 140 2 4 4 8 10 0.75
6 AF no 74 75 180 120 3 - 3 1 0 0
7 AF no 112 99 149 120 4 - 5 5 10 0.75
8 af yes 104 99 120 100 2 5 40 10 9 0.25
9 PSVT yes 75 85 233 129 2 24 5 7 1 0
10 WPW AVRT yes 80 75 130 115 2 2 3 3 0 0.25
11 sinus tachy - 117 101 120 90 1 - 8 8 0 0
12 sinus tachy - 60 80 190 150 2 - 16 4 10 0.5
Mean 82.3 83.7 169.7 127.7 2.3 7.9 11.3 6.8 5.5 0.4
SE 6.6 5.1 11.4 7.5 1.5 2.8 4.0 0.9 1.3 0.1  
 
af: Atrial fibrillation, AF: Atrial flutter, BP: blood pressure, HR: heart rate, JET: Junctional ectopic tachycardia,  
PDEⅢinhibitor: phosphodiesteraseⅢinhibitor、PSVT: Paroxysmal supraventricular tachycardia, SR: sinus rhythm, 
WPW AVRT: Wolff-Parkinson White Syndrome and Atrioventricular reciprocating tachycardia
17 
TOKUNAGA ET AL 
LANDIOLOL FOR PEDIATRIC TACHYARRHYTHMIA 
Figure 1. Heart rate, pre and post landiolol hydrochloride administration in each case. * p < 0.05 
 
 
 

